Cough-Variant Asthma: When Your Only Symptom Is a Persistent Cough

What Is Cough-Variant Asthma?

Cough-variant asthma (CVA) is a recognized subtype of asthma in which a persistent, dry, non-productive cough is the primary -- and often the only -- symptom. The classic triad of asthma (wheezing, shortness of breath, chest tightness) is absent or so subtle that patients and clinicians alike do not immediately associate the cough with asthma.

The term was first formally described in 1972 by Dr. Richard Glauser, who noted that some patients with airway hyperresponsiveness presented exclusively with chronic cough rather than overt bronchospasm. Decades of subsequent research have confirmed that CVA shares the same fundamental pathology as classic asthma: eosinophilic (and sometimes mixed) inflammation of the bronchial mucosa, smooth muscle hyperresponsiveness, and reversible airflow obstruction.

What distinguishes CVA is not the underlying disease but the predominant symptom expression. Heightened sensitivity of cough receptors in the large airways -- particularly C-fibers and rapidly adapting receptors (RARs) -- means that even modest airway irritation triggers a pronounced cough reflex before bronchoconstriction reaches the threshold needed to produce wheezing or dyspnea.

How Common Is Cough-Variant Asthma?

CVA is far more prevalent than most patients and clinicians realize. In studies of adults presenting with chronic cough (defined as cough lasting 8 weeks or more), CVA accounts for:

CVA can affect any age group but is most common in middle-aged adults. Women are diagnosed with CVA slightly more often than men, consistent with the pattern seen across all asthma subtypes. Children can also develop CVA; nocturnal cough in a child that disrupts sleep is a classic pediatric presentation.

Symptoms and Warning Signs of Cough-Variant Asthma

The signature of CVA is a dry, hacking, or tickling cough that persists for weeks to months. Because there is no wheezing or obvious breathing difficulty, patients often seek treatment multiple times for "bronchitis," "post-viral cough," or "acid reflux" before the correct diagnosis is made.

Classic Presentation

• Persistent dry, non-productive cough lasting 8 weeks or more
• Cough that is worse at night or in the early morning hours (2 to 5 AM)
• Cough triggered by cold air, exercise, laughing, talking, or strong smells
• Cough triggered by allergen exposure (pollen, pet dander, dust mites, mold)
• Cough following a respiratory infection (viral post-infectious CVA)
• Absence of wheeze, or wheeze so subtle the patient does not notice it
• Absence of significant breathlessness at rest
• Minimal or no mucus production
• Normal chest X-ray

Symptom Timing Patterns

Red Flags Requiring Urgent Evaluation

A cough that is CVA alone will not typically produce the following. Their presence requires additional workup before a CVA diagnosis can be confirmed:

• Blood in cough (hemoptysis) -- requires urgent imaging and bronchoscopy
• Significant unintentional weight loss alongside cough
• Progressive breathlessness at rest
• Purulent (green or yellow) sputum -- suggests infection
• Fever at cough onset
• Smoking history of 20 or more pack-years -- evaluate for COPD and lung cancer

Why CVA Is So Often Missed or Misdiagnosed

CVA is one of the most commonly delayed diagnoses in respiratory medicine. Studies suggest that patients with CVA see an average of three to four clinicians over 12 to 24 months before receiving the correct diagnosis.

The No-Wheeze Paradox

Clinicians are trained to listen for wheeze when considering asthma. In CVA, the airways are inflamed and hyperresponsive but bronchoconstriction does not reach the threshold that produces audible wheeze. A normal chest auscultation in a coughing patient powerfully steers clinicians away from an asthma diagnosis -- even when asthma is exactly what is present.

Conditions CVA Is Commonly Mistaken For

Causes and Triggers of Cough-Variant Asthma

CVA shares the same trigger profile as classic asthma. Triggers do not cause asthma itself but provoke cough in airways that are already inflamed and hyperresponsive.

Allergen Triggers

• Dust mites -- pervasive in Florida's humid indoor environments; year-round exposure with no seasonal reprieve
• Cockroach allergen -- a significant sensitizer in urban South Florida housing
• Pet dander -- cats and dogs; sensitization present in approximately 30% of asthmatic adults
• Mold spores -- Alternaria, Cladosporium, Aspergillus; elevated after rain events and in poorly ventilated interiors
• Pollen -- Bahia grass (peaks April to November in South FL), oak (February to April), ragweed (August to November)

Environmental and Irritant Triggers

• Cold or dry air -- air conditioning is a major indoor trigger in South Florida
• Exercise, especially sustained aerobic activity at high intensity
• Tobacco smoke and secondhand smoke
• Strong fragrances, cleaning products, and volatile organic compounds. See our guide on fragrance and chemical triggers for asthma.
• Air pollution -- ground-level ozone peaks in South Florida July through September
• Vaping and e-cigarette aerosol. Review vaping and asthma.

Physiologic Triggers

• Viral upper respiratory infections -- the most common trigger of CVA flare-ups
• Laughing, crying, or sustained talking
• Gastroesophageal reflux, which can coexist with CVA and amplify cough severity
• Emotional stress and anxiety
• Hormonal fluctuations in women (premenstrual asthma worsening is a recognized pattern)

What Is Happening in the Airways During CVA

Understanding why CVA produces cough rather than wheeze requires a brief look at the airway biology involved.

Eosinophilic Airway Inflammation

Like classic asthma, CVA is driven primarily by eosinophilic airway inflammation. Eosinophils release major basic protein, eosinophil cationic protein (ECP), and leukotrienes that damage the bronchial epithelium and sensitize sensory nerve endings. The subepithelial fibrosis and smooth muscle thickening visible on bronchial biopsy in CVA are histologically indistinguishable from classic asthma.

Heightened Cough Receptor Sensitivity

Patients with CVA consistently demonstrate a lower threshold for cough reflex activation than patients with classic asthma. C-fiber afferents in the large airways are sensitized by inflammatory mediators including bradykinin, prostaglandins, and substance P. This means a stimulus that produces mild, sub-symptomatic bronchoconstriction in a classic asthma patient will produce prominent coughing in a CVA patient -- before bronchoconstriction becomes severe enough to generate an audible wheeze.

Bronchial Hyperresponsiveness

CVA patients demonstrate methacholine PC20 values that fall in the same range as mild to moderate classic asthma, typically 2 to 8 mg/mL. The bronchoconstriction induced is often more cough-predominant than wheeze-predominant, reflecting not a quantitative difference in airway narrowing, but a qualitative difference in how the patient's sensory nervous system responds to that narrowing.

FeNO as a Biomarker

Fractional exhaled nitric oxide (FeNO) is elevated at or above 25 ppb in the majority of CVA patients, confirming Type 2 eosinophilic airway inflammation and predicting a strong response to inhaled corticosteroids. FeNO is a quick, non-invasive breath test. Learn more about FeNO testing at Advanced Asthma Clinic.

How Cough-Variant Asthma Is Diagnosed

Diagnosing CVA requires a systematic approach because standard spirometry can be entirely normal in patients who are asymptomatic at the time of testing. Dr. Frank Hull's evaluation of suspected CVA follows guidelines from the American College of Chest Physicians (ACCP) and the Global Initiative for Asthma (GINA).

Step 1 -- History and Clinical Assessment

A thorough history identifies cough duration, character, timing, triggers, and response to prior treatments. Key diagnostic questions include:

• Has the cough lasted 8 weeks or more?
• Is it worse at night or in the early morning?
• Is it triggered by cold air, exercise, or allergen exposure?
• Does the patient take an ACE inhibitor? (Drug-induced cough must be excluded before CVA workup proceeds)
• Is there a personal or family history of asthma, eczema, or allergic rhinitis?
• Has the cough failed to respond to empirical treatment for GERD or post-nasal drip?

Step 2 -- Spirometry with Bronchodilator Response

Spirometry measures FEV1, FVC, and the FEV1/FVC ratio. In CVA, spirometry is often normal between symptomatic episodes. A positive bronchodilator response (FEV1 increase of at least 12% and 200 mL after albuterol) supports reversible airway obstruction. Learn more about lung function testing at our clinic.

Step 3 -- Methacholine Challenge Test (Gold Standard)

The methacholine bronchial provocation test is the most sensitive diagnostic test for bronchial hyperresponsiveness. Inhaled methacholine is administered in increasing concentrations while FEV1 is monitored. The PC20 -- the concentration causing a 20% FEV1 fall -- is recorded:

• PC20 at or below 4 mg/mL -- confirms significant bronchial hyperresponsiveness; high likelihood of CVA
• PC20 4 to 16 mg/mL -- borderline; requires clinical correlation
• PC20 above 16 mg/mL -- essentially excludes clinically meaningful airway hyperresponsiveness

A negative methacholine challenge in a chronic cough patient shifts the differential toward UACS, GERD, NAEB, or other causes.

Step 4 -- FeNO Measurement

FeNO at or above 25 ppb confirms eosinophilic airway inflammation and predicts a good ICS response. The test is quick, non-invasive, and performed in-office. Explore FeNO testing for complete detail.

Step 5 -- Blood Eosinophil Count

A blood eosinophil count above 300 cells per microliter supports a Type 2 eosinophilic phenotype. In patients with high eosinophils who do not respond adequately to ICS, biologic therapy may be the next step. See our overview of blood eosinophil counts and asthma.

Step 6 -- Therapeutic Trial with ICS

In patients with a compelling clinical history and a positive methacholine challenge, a 4 to 8 week course of inhaled corticosteroids is considered both diagnostic and therapeutic. Cough resolution with ICS confirms CVA. Failure to respond after an adequate trial should prompt re-evaluation for alternative diagnoses.

Treatment Options for Cough-Variant Asthma

CVA is treated with the same medications used for classic asthma, following a stepwise approach guided by symptom frequency, severity, and biomarker profile. The goals are complete cough control, prevention of progression to classic asthma, and preservation of quality of life.

Inhaled Corticosteroids (ICS) -- First-Line Treatment

ICS directly reduce eosinophilic airway inflammation, lower cough receptor sensitivity, and decrease bronchial hyperresponsiveness. Clinical response rates in CVA are 80 to 90 percent. Patients typically notice meaningful cough reduction within 2 to 4 weeks; full effect may require 8 to 12 weeks of consistent use.

Commonly prescribed ICS options for CVA include:

• Fluticasone propionate (Flovent) -- 88 to 220 mcg twice daily
• Budesonide (Pulmicort) -- 180 to 360 mcg twice daily
• Beclomethasone dipropionate (QVAR) -- 40 to 80 mcg twice daily
• Mometasone furoate (Asmanex) -- 110 to 220 mcg once or twice daily

Treatment duration should be at least 6 to 12 months to minimize relapse and reduce the risk of progression to classic asthma. For a full overview, read our inhaled corticosteroids guide.

Short-Acting Bronchodilators (SABA) for Acute Relief

Albuterol MDI provides rapid relief during acute cough episodes by reversing bronchoconstriction and suppressing cough receptor activation. It is not a substitute for ICS. Patients using SABA more than twice per week should be reassessed and their maintenance therapy stepped up. See our overview of short-acting bronchodilators.

Leukotriene Receptor Antagonists (LTRA)

Montelukast (Singulair) inhibits leukotriene pathways that drive eosinophilic inflammation and directly sensitize cough receptors. It is useful as an add-on to ICS in patients with incomplete cough control, as an ICS alternative for patients with ICS intolerance, and as a first-line option in mild intermittent CVA. Note: Montelukast carries an FDA Boxed Warning for serious neuropsychiatric events; patients must be counseled prior to initiation. See our full montelukast guide.

ICS Plus LABA Combination Therapy

For CVA not controlled on medium-dose ICS alone, adding a long-acting bronchodilator via a combination inhaler -- such as fluticasone/salmeterol (Advair), budesonide/formoterol (Symbicort), or mometasone/formoterol (Dulera) -- provides additional anti-inflammatory and bronchodilatory benefit. LABAs must always be combined with ICS and never used as monotherapy in asthma. Learn more about long-acting bronchodilators.

Biologic Therapy for Refractory CVA

A minority of CVA patients have persistent cough and high eosinophil counts despite optimized inhaled therapy. For these patients, biologic agents targeting the Type 2 inflammatory pathway may be appropriate:

• Mepolizumab (Nucala) -- anti-IL-5; monthly subcutaneous injection; reduces blood and airway eosinophil counts
• Benralizumab (Fasenra) -- anti-IL-5 receptor alpha; produces rapid eosinophil depletion within days
• Dupilumab (Dupixent) -- anti-IL-4/IL-13; particularly effective in atopic patients with coexisting eczema or allergic rhinitis
• Tezepelumab (Tezspire) -- anti-TSLP; broadest efficacy across all asthma phenotypes including non-eosinophilic

Biologic therapy is generally reserved for patients meeting criteria for severe uncontrolled asthma. Review our biologic therapy guide and biologic comparison chart for eligibility criteria and side-by-side comparisons.

Non-Pharmacologic Strategies

• Allergen avoidance: HEPA air purifiers, dust-mite encasements, pet restriction in bedrooms. See our air purifier guide.
• Humidity control: Maintaining indoor humidity at 40 to 50 percent discourages dust mite and mold growth -- especially important in South Florida. Review our humidity and mold guide.
• Cough diary: Recording date, time, activity, location, and potential exposures helps identify personal triggers and guides adjustments to the management plan.
• Cough suppression therapy: Patients who cough frequently can develop a habitual cough that persists even after inflammation resolves. Speech-language pathology techniques -- including controlled breathing, suppression maneuvers, and vocal hygiene -- are effective adjuncts for refractory cough habit.
• GERD management: Where gastroesophageal reflux coexists with CVA, acid suppression with a PPI reduces the reflux component of cough while ICS addresses the airway inflammation component.

Will Cough-Variant Asthma Progress to Classic Asthma?

This is the most important prognostic question for CVA patients. Long-term follow-up data demonstrate:

• Approximately 30 to 40 percent of untreated CVA patients develop classic asthma with wheezing within 5 years
• Patients treated consistently with ICS show a significantly lower progression rate
• Lower baseline PC20 (greater airway hyperresponsiveness) correlates with higher progression risk
• Allergen sensitization and elevated FeNO at diagnosis are additional predictors of progression
• Patients who relapse after stopping ICS are at increased risk of full classic asthma phenotype development

The practical message for patients: CVA is a real asthma diagnosis requiring real asthma treatment. Consistent use of prescribed inhaled corticosteroids is the single most effective intervention both for controlling current symptoms and for reducing the long-term risk of developing classic asthma with wheezing. Always follow your physician's guidance on treatment duration and do not discontinue ICS without a formal review.

Cough-Variant Asthma in South Florida

Broward County and the wider South Florida region present a specific environmental challenge for CVA patients. Several regional factors sustain airway inflammation and cough trigger exposure throughout the year.

Year-Round Allergen Burden

Unlike northern states where pollen seasons are distinct and winter provides a low-allergen period, South Florida's subtropical climate sustains allergen exposure nearly continuously:

• Bahia grass pollen -- peaks April through November; South Florida carries one of the highest Bahia grass exposures in the continental United States
• Dust mites -- thrive at temperatures above 70 degrees Fahrenheit and relative humidity above 50 percent; South Florida's climate is permanently optimal for dust mite proliferation
• Mold spores -- elevated year-round; surge after summer afternoon thunderstorms and following hurricane-season rain events (June through November)
• Australian pine and melaleuca -- invasive species with documented allergenic pollen in Broward County parks and roadsides

Indoor Air Conditioning as a CVA Trigger

South Floridians spend the majority of time in heavily air-conditioned environments. Cold, dry air from air conditioning is a direct trigger for cough in CVA patients. Many patients notice their cough worsens in offices, shopping centers, and cars -- only to improve during outdoor mild-weather months. This pattern is highly suggestive of CVA and is a key feature in the diagnostic history that Dr. Hull looks for in South Florida patients.

Hurricane Season and Post-Disaster Mold

Major storms accelerate mold colonization in water-damaged structures. Post-hurricane mold exposure can trigger CVA onset or significantly worsen existing CVA for months to years following a storm. Review our hurricane season asthma guide for storm preparedness strategies.

Summer Ozone Peaks

Ground-level ozone concentrations in South Florida peak July through September. Ozone is a potent airway irritant that increases cough receptor sensitivity and worsens CVA symptoms in outdoor workers, runners, and others spending time outside during peak hours (10 AM to 4 PM). Checking the Florida DEP air quality index before outdoor activity is a simple protective measure for CVA patients.

When to See a Specialist for Chronic Cough

A visit to a pulmonologist or asthma specialist is warranted when one or more of the following apply:

• Cough has persisted for 8 weeks or more
• Cough has not responded to a trial of antihistamine/decongestant for post-nasal drip
• Cough has not responded to a 4-week PPI trial for suspected GERD
• Cough is worse at night, waking you from sleep
• Cough is triggered by cold air, exercise, laughing, or known allergens
• Cough is disrupting work, sleep, or social activities
• You have a personal or family history of asthma, eczema, or hay fever
• You were previously told you had "chronic bronchitis" or "recurrent chest infections" with no documented pathogen
• Cough started or intensified after a respiratory infection you never fully recovered from

At Advanced Asthma Clinic in Plantation, FL, Dr. Frank Hull offers same-session spirometry, FeNO measurement, and blood eosinophil profiling. Methacholine challenge testing is available on-site -- no referral to an outside laboratory required. Call 954-522-7226 or book online below to schedule a comprehensive chronic cough evaluation.

Frequently Asked Questions About Cough-Variant Asthma